Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 and SYLF domain containing 1 (SH3YL1)
- Target
- SH3YL1
- Molecular classification
- Other (adaptor/scaffolding protein; not a receptor, enzyme, ion channel, or transporter)
01
Overview
SH3 and SYLF domain containing 1 (SH3YL1) is a cytoplasmic adaptor-like protein containing SH3 and SYLF domains, involved in phosphatidylinositol binding and phosphatase interaction. It localizes to the plasma membrane, regulates dorsal ruffle assembly, and participates in endocytosis and membrane remodeling. SH3YL1 has been identified as a regulator of NOX4, contributing to ROS production and implicated in kidney pathophysiology, including diabetic nephropathy and thrombophilia. It serves as a novel biomarker for renal outcomes in diabetic kidney disease, with higher plasma or urinary levels correlating to worse renal prognosis in type 2 diabetes. No direct therapeutics targeting SH3YL1 are known; its disease relevance is primarily as a prognostic/predictive biomarker rather than a therapeutic target.
- Other names
- SH3YL1SH3 domain-containing YSC84-like protein 1RAYDKFZP586F1318SH3 domain containing, Ysc84-like 1
02
Mechanism of action
null (no drugs known to act directly on this molecule)
03
Biological functions
Phosphatidylinositol bindingPhosphatase bindingRegulation of ruffle/dorsal ruffle assemblyInvolvement in membrane invagination and endosomal processingRegulator of NOX4-mediated oxidative signaling
04
Disease associations
Diabetic nephropathy/chronic kidney disease (biomarker, possible mediator)ThrombophiliaOther renal diseases (as biomarker, not as a direct pathogenic driver)
05
Biomarkers
Plasma SH3YL1 for diabetic nephropathy and renal outcome predictionUrinary SH3YL1-to-creatinine ratio (USCR) for CKD and diabetic nephropathy
Beyond the preview
Go deeper on SH3 and SYLF domain containing 1 (SH3YL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH3 and SYLF domain containing 1 (SH3YL1).